Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Ningetinib
Synonyms
Therapy Description

Ningetinib (CT053PTSA) inhibits MET, VEGFR2, AXL, and FLT3, which potentially reduces tumor cell growth (PMID: 36341335, PMID: 38978049).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Ningetinib CT053PTSA|CT-053-PTSA AXL Inhibitor 30 FLT3 Inhibitor 69 MET Inhibitor 59 VEGFR2 Inhibitor 37 Ningetinib (CT053PTSA) inhibits MET, VEGFR2, AXL, and FLT3, which potentially reduces tumor cell growth (PMID: 36341335, PMID: 38978049).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 exon 14 ins FLT3 F691L hematologic cancer sensitive Ningetinib Preclinical Actionable In a preclinical study, Ningetinib (CT053PTSA) inhibited Flt3 downstream signaling and viability in a cell line expressing a FLT3-ITD and FLT3 F691L in culture and decreased leukemic burden and prolonged survival in a mouse model (PMID: 38978049). 38978049
FLT3 exon 14 ins FLT3 F691L acute myeloid leukemia sensitive Ningetinib Preclinical - Cell line xenograft Actionable In a preclinical study, Ningetinib (CT053PTSA) decreased leukemic burden in a cell line xenograft model of acute myeloid leukemia harboring a FLT3-ITD and expressing FLT3 F691L (PMID: 38978049). 38978049
FLT3 exon 14 ins FLT3 D835Y hematologic cancer sensitive Ningetinib Preclinical - Cell culture Actionable In a preclinical study, Ningetinib (CT053PTSA) inhibited Flt3 downstream signaling and viability in a cell line expressing a FLT3-ITD and FLT3 D835Y in culture (PMID: 38978049). 38978049
FLT3 exon 14 ins FLT3 Y842C hematologic cancer sensitive Ningetinib Preclinical - Cell culture Actionable In a preclinical study, Ningetinib (CT053PTSA) inhibited Flt3 downstream signaling and viability in a cell line expressing a FLT3-ITD and FLT3 Y842C in culture (PMID: 38978049). 38978049
FLT3 exon 14 ins FLT3 N676D hematologic cancer sensitive Ningetinib Preclinical - Cell culture Actionable In a preclinical study, Ningetinib (CT053PTSA) inhibited viability in a cell line expressing a FLT3-ITD and FLT3 N676D in culture (PMID: 38978049). 38978049
FLT3 exon 14 ins acute myeloid leukemia sensitive Ningetinib Preclinical - Cell line xenograft Actionable In a preclinical study, Ningetinib (CT053PTSA) induced cell cycle arrest and apoptosis and inhibited Flt3 downstream signaling and viability in acute myeloid leukemia cell lines harboring a FLT3-ITD, inhibited Flt3 downstream signaling and proliferation in patient-derived cells in culture, and decreased leukemic burden in a cell line xenograft model (PMID: 38978049). 38978049
FLT3 exon 14 ins FLT3 D835V hematologic cancer sensitive Ningetinib Preclinical - Cell culture Actionable In a preclinical study, Ningetinib (CT053PTSA) inhibited Flt3 downstream signaling and viability in a cell line expressing a FLT3-ITD and FLT3 D835V in culture (PMID: 38978049). 38978049
FLT3 exon 14 ins hematologic cancer sensitive Ningetinib Preclinical Actionable In a preclinical study, Ningetinib (CT053PTSA) inhibited Flt3 downstream signaling and viability in a cell line expressing a FLT3-ITD in culture and decreased leukemic burden in a mouse model (PMID: 38978049). 38978049

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries


Additional content available in CKB BOOST